Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Figlin · SciRah

Researcher profile · Semantic Scholar

R. Figlin

Share profile

R. Figlin — researcher profile on SciRah

h-index: 100
Works: 568
Citations: 48K

Most-cited papers

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Sung-Bae Kim, R. Dent, S. Im, M. Espié +49 more
2017The Lancet Oncology433 citations Open access
Semantic Scholar
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
K. Courtney, J. Infante, E. Lam, R. Figlin +8 more
2017Journal of Clinical Oncology277 citations Open access
Semantic Scholar
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
B. Rini, D. Battle, R. Figlin, D. George +14 more
2019Journal of Immunotherapy for Cancer223 citations Open access
Semantic Scholar
Targeted therapies for renal cell carcinoma
E. Posadas, S. Limvorasak, R. Figlin
2017Nature Reviews Nephrology213 citations
Semantic Scholar
Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients
Gillian Gresham, A. Hendifar, B. Spiegel, E. Neeman +6 more
2018npj Digital Medicine162 citations Open access
Semantic Scholar
HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor in Clear Cell Renal Cell Carcinoma Patients
K. Courtney, Yuanqing Ma, Alberto de Léon, A. Christie +24 more
2019Clinical Cancer Research146 citations Open access
Semantic Scholar
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
N. Tannir, N. Agarwal, C. Porta, N. Lawrence +18 more
2022JAMA Oncology140 citations Open access
Semantic Scholar
Wearable activity monitors in oncology trials: Current use of an emerging technology
Gillian Gresham, J. Schrack, Louise M. Gresham, A. Shinde +6 more
2017Contemporary Clinical Trials133 citations Open access
Semantic Scholar
Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
R. Motzer, B. Escudier, A. Gannon, R. Figlin
2017The Oncologist93 citations Open access
Semantic Scholar
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
B. Rini, D. McDermott, H. Hammers, W. Bro +16 more
2016Journal of Immunotherapy for Cancer83 citations Open access
Semantic Scholar
Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.
D. Lakdawalla, J. Shafrin, Ning-Qi Hou, D. Peneva +5 more
2017Value in Health79 citations Open access
Semantic Scholar
Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer.
E. Neeman, Gillian Gresham, Navasard Ovasapians, A. Hendifar +3 more
2019The Oncologist76 citations Open access
Semantic Scholar
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
T. Choueiri, D. McDermott, J. Merchan, T. Bauer +10 more
2023The Lancet Oncology68 citations
Semantic Scholar
Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma
R. Figlin, N. Tannir, R. Uzzo, S. Tykodi +14 more
2020Clinical Cancer Research68 citations
Semantic Scholar
COVID-19 and androgen targeted therapy for prostate cancer patients
N. Bhowmick, J. Oft, T. Dorff, S. Pal +5 more
2020Endocrine-Related Cancer65 citations Open access
Semantic Scholar
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
M. Voss, A. Hussain, N. Vogelzang, J.-L. Lee +16 more
2017Annals of Oncology60 citations Open access
Semantic Scholar
Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance
Min Young Lee, Austin Yeon, Muhammad Shahid, Eunho Cho +4 more
2018OncoTarget56 citations Open access
Semantic Scholar
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy
R. Motzer, M. Schmidinger, M. Eto, C. Suárez +5 more
2023Future Oncology51 citations Open access
Semantic Scholar
Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group
B. Rini, Thomas E. Hutson, R. Figlin, M. Lechuga +4 more
2018Clinical Genitourinary Cancer46 citations Open access
Semantic Scholar
Heterogeneity of Patients With Intermediate‐Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib
A. Sella, D. Michaelson, E. Matczak, R. Simantov +2 more
2017Clinical Genitourinary Cancer40 citations
Semantic Scholar
A novel machine learning approach reveals latent vascular phenotypes predictive of renal cancer outcome
N. Ing, Fangjin Huang, A. Conley, S. You +8 more
2017Scientific Reports37 citations Open access
Semantic Scholar
CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic
N. Tannir, N. Agarwal, C. Porta, N. Lawrence +16 more
202128 citations
Semantic Scholar
Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
D. Goldstein, J. Rosenberg, R. Figlin, R. Townsend +3 more
2016European Journal of Cancer27 citations
Semantic Scholar
Gut microbiome, antibiotic use, and immunotherapy responsiveness in cancer.
Jarred P. Reed, Suzanne Devkota, R. Figlin
2019Annals of Translational Medicine26 citations Open access
Semantic Scholar
Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.
B. Rini, L. Appleman, R. Figlin, E. Plimack +6 more
2019Journal of Clinical Oncology22 citations
Semantic Scholar
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
M. Voss, A. Hussain, N. Vogelzang, J. L. Lee +16 more
201720 citations Open access
Semantic Scholar
Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma
An Uche, C. Sila, T. Tanoura, James J. Yeh +4 more
2019Case Reports in Urology19 citations Open access
Semantic Scholar
Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials
N. Tannir, R. Figlin, M. Gore, M. D. Michaelson +6 more
2017Clinical Genitourinary Cancer17 citations Open access
Semantic Scholar
Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection
A. LeVee, Ching-Ying Lin, E. Posadas, R. Figlin +8 more
2021OncoTargets and Therapy15 citations Open access
Semantic Scholar
Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer
E. Vail, Jian-Bo Song, Jing Xu, Joseph S. Frye +11 more
2020Targeted oncology15 citations
Semantic Scholar
Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough?
D. Patel, R. Figlin, Hyung L. Kim
2016Clinical advances in hematology & oncology : H&O15 citations
Semantic Scholar
Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma.
J. Adashek, M. Salgia, E. Posadas, R. Figlin +1 more
2019Clinical Genitourinary Cancer14 citations
Semantic Scholar
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma
A. Zurita, R. Gagnon, Y. Liu, H. Tran +6 more
2017British Journal of Cancer14 citations Open access
Semantic Scholar
Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer
R. A. Kumbla, R. Figlin, E. Posadas
2016Drugs13 citations
Semantic Scholar
The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.
Thomas E. Hutson, G. Thoreson, R. Figlin, B. Rini
2016American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting13 citations
Semantic Scholar
Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials
P. Bono, S. Oudard, I. Bodrogi, Thomas E. Hutson +13 more
2016Clinical Genitourinary Cancer12 citations Open access
Semantic Scholar
Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma
Jarred P. Reed, E. Posadas, R. Figlin
2019Expert Review of Anticancer Therapy10 citations
Semantic Scholar
1137OInterim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC)
R. Figlin, C. Nicolette, N. Tannir, S. Tykodi +8 more
201710 citations Open access
Semantic Scholar
CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.
N. Tannir, N. Agarwal, N. Dawson, R. Motzer +13 more
2019Journal of Clinical Oncology9 citations
Semantic Scholar
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
J. Adashek, J. Breunig, E. Posadas, N. Bhowmick +5 more
2022Drugs8 citations
Semantic Scholar
Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?
J. Adashek, Jarred P. Reed, A. Tandon, S. Freedland +6 more
2020Clinical Genitourinary Cancer8 citations Open access
Semantic Scholar
Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial
R. Motzer, R. Figlin, J. Martini, S. Hariharan +4 more
2017Clinical Genitourinary Cancer8 citations
Semantic Scholar
Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma.
Patrick K. Tamukong, Paige K. Kuhlmann, S. You, Sheng-Chen Su +10 more
2022Urologic oncology7 citations
Semantic Scholar
Brain Metastases in Renal Cell Carcinoma: Immunotherapy Responsiveness Is Multifactorial and Heterogeneous.
Jarred P. Reed, E. Posadas, R. Figlin
2019Journal of Clinical Oncology7 citations Open access
Semantic Scholar
Circulating tumor cells in prostate cancer: beyond enumeration.
Jie-Fu Chen, Yi-Tsung Lu, Shirley Cheng, Hsian-Rong Tseng +2 more
2017Clinical advances in hematology & oncology : H&O7 citations
Semantic Scholar
Correlating wearable activity monitor data with PROMIS detected distress and physical functioning in advanced cancer patients.
A. Shinde, Gillian Gresham, A. Hendifar, Quan-Lin Li +6 more
20177 citations
Semantic Scholar
The value of surrogate endpoints for predicting real-world survival across five cancer types
J. Shafrin, R. Brookmeyer, D. Peneva, Jinhee Park +3 more
2016Current Medical Research and Opinion7 citations
Semantic Scholar
Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
J. Gong, E. Posadas, N. Bhowmick, Hyung L. Kim +7 more
2021Oncology6 citations
Semantic Scholar
Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure.
B. Rini, E. Abel, L. Albiges, A. Bex +13 more
2020Clinical Genitourinary Cancer6 citations
Semantic Scholar
Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial.
D. George, A. Pantuck, R. Figlin, B. Escudier +6 more
2018Annals of Oncology6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Posadas×12
Invite
E. Posadas — researcher profile on SciRah
R. Motzer×11
Invite
R. Motzer — researcher profile on SciRah
B. Rini×10
Invite
B. Rini — researcher profile on SciRah
J. Gong×8
Invite
J. Gong — researcher profile on SciRah

×6

Invite

N. Tannir — researcher profile on SciRah

Invite

B. Escudier — researcher profile on SciRah

Thomas E. Hutson×6

Invite

Thomas E. Hutson — researcher profile on SciRah

Invite

N. Bhowmick — researcher profile on SciRah

Invite

C. Wood — researcher profile on SciRah

Invite

N. Agarwal — researcher profile on SciRah

S. Freedland×5

Invite

S. Freedland — researcher profile on SciRah

Invite

T. Choueiri — researcher profile on SciRah